Section ofComparative Medicine 349
peritoneal cavity, to culture the test mixture; and (3) the dominant lethal test, in which male mice or rats are treated with the drug and mated with a series of (usually untreated) females. The latter are killed in mid-pregnancy and counts of implantation and resorption sites, and of viable feetuses are made.
The predictive value of such tests has yet to be established, as have their advantages over the current well-conducted reproductive and teratological tests used in evaluating safety. REFERENCES Fitzhugh 0 G (1959) The Biological Division of the Weilcome Research Laboratories is the largest single manufacturer of vaccines, antisera and diagnostic reagents in this country. It is also concerned with research and development aimed at understanding more about the basic mechanisms of immunity and devising more effective means of producing clinical immunity or tolerance, so that existing products may be improved and new ones prepared.
During the year 1969-70 we used very large numbers ofanimals which cost us about £200,000; in addition there is the cost of their maintenance, housing and feeding whilst in our laboratories. The economic incentive to reduce the number of animals used is therefore strong, yet the numbers used increase inexorably.
The total numbers that we use, including animals that are used to provide meat for media production or normal serum, amount to over 300,000. In addition, we use 750,000 fertile eggs. Usage has been divided into several classes and it is found that the large majority of the animals used are employed in tests to establish potency and safety of products.
The quality of animals is of vital importance, especially for the provision of substrate for virus vaccine production or testing. The solutionpartial only at presentto this problem is the substitution of tissue cultures for animals. Cells can be established in continuous culture and stored at low temperatures whilst aliquots are tested exhaustively for freedom from microbial contamination and general safety. The use of such preserved cells has been in large scale use for veterinary virus vaccines like those for foot and mouth and Newcastle diseases. Last year a living attenuated rubella vaccine grown in a human diploid cell strain W138 was licensed in this country. This has reduced the dependence on variable animal hosts and introduced to the substrate for virus vaccine the same seed concept that has been found necessary to control the quality of attenuated microbes. In the early days of vaccinia or BCG vaccines serial passage of the strain occurred, with resulting variations in quality. It gradually became possible, as good techniques of preservation were developed, to produce stable master seeds of vaccine shown to be effective and safe in man and use these for vaccine production. Now a similar seed system can be employed for the cell substrate used for the production of virus vaccines.
Animals have to be used for many purposes, particularly for safety and potency testing. Any reduction in their numbers for these purposes has to come from using larger batches of vaccine, or the improvement of their quality so that more uniform and regular results are obtained. Similar improvements in quality are being sought in other applications so that, for example, higher antibody levels are achieved from animals used for antibody production. By comparison, the usage of animals for research programmes is relatively small, but none the less vital to continued progress in the prevention of disease of man and animals. Medicines mean medicinal products as defined in Section 130 of the Medicines Act, 1968. In the context of this paper, only a limited area of such a wide group will be referred to. Almost any animals can be and have been involved but the most commonly used are mice, rats, guinea-pigs
